
    
      PLX038 is an investigational drug product that has demonstrated reasonable antitumor activity
      in preclinical colorectal, gastric and lung tumor models in animals. This is a first in human
      trial to determine the maximum, safest dose of PLX038 IV that can be administered to patients
      either once every 3 weeks or once every 2 weeks.
    
  